“How confident are you in the 32.7% figure in severe

New Post Public Reply Private Reply Replies (0) Message Board
ClosetInvestor CDiddy #73111
580
“How confident are you in the 32.7% figure in severe critical?”

32.7% is for the overall hospitalized death rate in COVID19 (According to the CDC) and does not specify between moderate, severe, or critical classification. The 32.7% likely includes some patients who died from a sudden cardiopulmonary event (or similar event) while hospitalized, but classified in the moderate category.

“Does anyone have the studies handy if mortality in the SOC severe/critical?”

This has been researched here extensively and it’s been hard to pin down. There are studies from around the world with varying number for severe and varying numbers for critical. There’s papers showing a decrease in mortality due to SOC, but another paper shows mortality unchanged in hospitals that are near or over capacity. I won’t attempt to identify an overall percent or a percent for each classification, but I’m a few of the others may post numbers/links.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Madrigal Pharmaceuticals Rewards New Employees with Equity Awards

Updated Category News Views 100

Overview of Equity Inducement Awards Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a leading biopharmaceutical organization, has recently initiated equity inducement awards to welcome new talent to its dynamic team. This initiative demonstrates Madrigal's commitment to fostering a strong workforce geared towards tackling significant health challenges related to metabolic...

Continue Reading
Boston Metal Welcomes Roy Harvey to Enhance Board Leadership

Updated Category News Views 202

Boston Metal Appoints Industry Leader Roy Harvey Boston Metal, a prominent technology company that is transforming the landscape of global metals production, has made a significant move by appointing Roy Harvey to its Board of Directors. This decision is pivotal as Boston Metal gears up for the commercial rollout of its groundbreaking Molten Oxide Electrolysis (MOE)...

Continue Reading
RBL LLC Partners with Carnrite Ventures for Biotech Growth

Updated Category News Views 125

RBL LLC Partners with Carnrite Ventures for Biotech Growth RBL LLC, a leading biotech venture creation studio, is excited to announce a significant investment from Carnrite Ventures. This partnership aims to enhance the rapid development of their robust pipeline of innovative therapeutic companies. According to Paul Wotton, the managing partner at RBL, "Carnrite's...

Continue Reading
OncoC4 and AcroImmune Merger: A Milestone in Immunotherapy

Updated Category News Views 106

Introducing the OncoC4 and AcroImmune Merger OncoC4, Inc. has just announced a thrilling merger with AcroImmune, a strategic union that promises to significantly boost OncoC4's standing in the biopharmaceutical sector. This collaboration brings together two companies dedicated to pioneering advancements in cancer treatment, with a special focus on developing unique...

Continue Reading
Rezolve AI Celebrates Major Investment Transforming AI Landscape

Updated Category News Views 92

Rezolve AI Excited About $30 Billion AI Investment Rezolve AI (NASDAQ: RZLV), well-known for its cutting-edge AI-driven commerce solutions, is enthusiastic about the recent announcement from Microsoft and BlackRock. These influential tech companies plan to invest $30 billion into AI infrastructure, a decision that could profoundly alter the landscape of the artificial...

Continue Reading